Home/Pipeline/Tumor Ecosystem Disruptors

Tumor Ecosystem Disruptors

Solid Tumors

PreclinicalActive

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Active

Company

Alixia

About Alixia

Alixia is pioneering a novel approach to oncology by targeting the tumor as a dynamic ecosystem, addressing the limitations of current precision medicine which benefits only a small fraction of patients. The company's integrated research platform combines biology, biophysics, and computational chemistry to discover 'tumor ecosystem disruptors' that impact multiple cell types within the tumor microenvironment. With a preclinical pipeline focused on cancer and related age-related diseases, Alixia is led by a team with strong scientific and operational expertise, positioning itself to tackle the complex challenge of therapeutic resistance.

View full company profile

Therapeutic Areas

Oncology Neurodegeneration Inflammation

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed